Condition: Relapsing Remitting Multiple Sclerosis (RRMS) · Sponsor: Glostrup University Hospital, Copenhagen
This study, iPROACT-MS, is part of the iPROACT group of clinical trials aiming to investigate the effects of oral supplementation with indole-3-propionic acid (IPA) in humans. IPA is naturally produced as a gut bacterial metabolite with the amino acid tryptophan as substrate. The primary aim of iPROACT-MS is to investigate whether patients with relapsing-remitting multiple sclerosis (RRMS) can benefit from supplementation with IPA. The hypothesis is that supplementation with IPA will protect against MS-related disease activity, neurodegeneration and metabolic abnormalities. Secondary, iPROACT-MS aims at elucidating the complex relationships between lifestyle, gut microbial factors, inflammation, oxidative stress, metabolic health, MS disease severity and MS disease activity.
This description comes directly from the study's public registry record.
Jette Lautrup Frederiksen, MD, dr.med, professor · +4538633041 · jette.lautrup.battistini@regionh.dk
Moschoula Passali, MSc, PhD · +45 38633467 · moschoula.passali@regionh.dk
Always discuss trial participation with your own doctor first.
| Glostrup Hospital | Glostrup Municipality, Denmark | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07318129